Premonopausal Hormone Levels and Risk of Breast Cancer

绝经前激素水平和乳腺癌风险

• 批准号: 7844510
• 负责人: Susan E Hankinson
• 金额: $ 431.68万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7844510
• 关键词: Address; Age; American; Biological Markers; Blood; Cancer Etiology; Chronic Disease; Cohort Studies; Collection; Contraceptive Usage; Development; Disease; Elderly; Equipment; Estradiol; Evaluation; Funding; Future; Goals; Gonadal Steroid Hormones; Grant; Hormonal; Hormones; Human Resources; Inflammatory; Lead; Life; Living Wills; Longevity; Mails; Malignant Neoplasms; Measures; Melatonin; Menopause; Menstrual cycle; Methods; Nature; Nurses' Health Study; Nutritional; Obesity; Occupations; Oral Contraceptives; Participant; Pharmaceutical Preparations; Plasma; Positioning Attribute; Postmenopause; Premenopause; Prevention; Process; Prolactin; Questionnaires; Recovery; Relative (related person); Research Personnel; Resources; Risk; Role; Sampling; Specimen; Staging; Testosterone; Time; Urine; Woman; anticancer research; base; biobank; cancer risk; cohort; disorder risk; follow-up; interest; lifestyle factors; malignant breast neoplasm; meetings; member; middle age; parent grant; prospective; public health relevance; repository; response; urinary

DESCRIPTION (provided by investigator): This applications is a Competitive Revision to R01 CA67262, entitled "Premenopausal Hormone Levels and Risk of Breast Cancer", in response to NOT-OD-09-058, "The Availability of Recovery Act Funds for Competitive Revision Applications". The parent grant funds the assessment of a range of premenopausal hormones (e.g., plasma sex steroids) in relation to breast cancer risk in the Nurses' Health Study II (NHSII) cohort. The NHSII cohort consists of 116,430 women who have been followed biennially by questionnaire since 1989. Between 1996 and 1999 (and funded by CA67262), we collected blood and urine samples from 29,611 NHSII participants. In the current application, we propose to collect a second set of blood and urine samples from these women, which will substantially enhance the ability to examine biomarker exposures at different points in life in relation to cancer risk. Women were 32 to 54 years old at the first collection and were predominantly premenopausal; they will be 46 to 66 years old and predominantly postmenopausal at the time of the proposed collection. The collection of a second set of biospecimens from NHSII women would form one of the only large biorepository in the world to have samples from the same women 10-15 years apart; we anticipate based on prior biospecimen collection response rates to obtain samples from over 19,000 women. Further, many of the sample sets would be paired pre- and postmenopausal samples (n~13,000 women). With continued follow-up of the cohort, we would be in a unique position to assess temporal associations between biomarkers and disease risk, which has particular relevance to cancer given its multi-stage carcinogenic process. In addition, having a mid-life sample and a sample in later life will assist in determining the importance of age in modifying biomarker-disease relationships. Further, of substantial interest in breast cancer research is whether endogenous hormones measured during pre- and post menopause are independently associated with breast cancer risk, and whether potential interactions exist between the two. This application meets the goals of the American Recovery and Reinvestment Act by hiring three new staff members, purchasing equipment from a U.S. company, and using another U.S. company to mail blood collection kits and process the returned samples. Ultimately, this resource would lead to the development of scientific aims for future grants that would address important scientific questions, create new jobs, provide continuing support for existing personnel, and create a powerful biorepository for studying associations between biomarkers and disease in women. PUBLIC HEALTH RELEVANCE: This project would create a blood and urine repository in the Nurses' Health Study II containing samples from the same women collected about 10 to 15 years apart, nearly 70 percent of which would be paired pre- and postmenopausal samples. This resource could be used to answer important scientific questions relating to biomarker exposures and cancer risk, to better understand how cancer develops and identify potential prevention methods.

描述（由研究者提供）：本申请是对R 01 CA 67262的竞争性修订，标题为“绝经前激素水平和乳腺癌风险”，以响应NOT-OD-09-058“竞争性修订申请的恢复法案资金可用性”。父母补助金资助评估一系列绝经前激素（例如，血浆性类固醇）与护士健康研究II（NHSII）队列中乳腺癌风险的关系。NHSII队列由116，430名女性组成，自1989年以来每两年进行一次问卷调查。在1996年至1999年期间（由CA 67262资助），我们收集了29，611名NHSII参与者的血液和尿液样本。在本申请中，我们建议从这些女性中收集第二组血液和尿液样本，这将大大提高检查生命中不同时间点生物标志物暴露与癌症风险的能力。首次采集时女性年龄为32 - 54岁，主要为绝经前;拟定采集时女性年龄为46 - 66岁，主要为绝经后。从NHSII妇女中收集第二组生物标本将成为世界上唯一一个大型生物储存库，其样本来自相隔10-15年的同一妇女;我们预计根据以前的生物标本收集响应率，将从19，000多名妇女中获得样本。此外，许多样本集将是绝经前和绝经后的配对样本（n~ 13，000名女性）。随着对该队列的持续随访，我们将处于一个独特的位置来评估生物标志物与疾病风险之间的时间关联，鉴于其多阶段致癌过程，这与癌症特别相关。此外，拥有中年样本和晚年样本将有助于确定年龄在改变生物标志物-疾病关系中的重要性。此外，在乳腺癌研究中，人们非常感兴趣的是绝经前后测量的内源性激素是否与乳腺癌风险独立相关，以及两者之间是否存在潜在的相互作用。该申请符合美国复苏和再投资法案的目标，雇用了三名新工作人员，从一家美国公司购买设备，并使用另一家美国公司邮寄血液采集套件和处理返回的样本。最终，这一资源将导致未来赠款的科学目标的发展，这些赠款将解决重要的科学问题，创造新的就业机会，为现有人员提供持续的支持，并为研究生物标志物与妇女疾病之间的关联创造一个强大的生物储存库。 公共卫生相关性：该项目将在护士健康研究II中创建一个血液和尿液储存库，其中包含间隔约10至15年收集的相同妇女的样本，其中近70%将是绝经前后的配对样本。该资源可用于回答与生物标志物暴露和癌症风险相关的重要科学问题，以更好地了解癌症如何发展并确定潜在的预防方法。